Alpha Tau Medical Ltd. — Form 6-K Summary
Reporting period: Form 6-K furnished on May 26, 2022, covering the month of May 2022. The filing reports issuance of a press release titled “Alpha Tau Medical Announces First Quarter 2022 Financial Results and Provides Corporate Update.”
Business Context
Alpha Tau Medical Ltd. is an Israel-based medical technology company. The filing identifies Nasdaq ticker DRTS and states that the company files annual reports on Form 20-F.
Financial Metrics
The filing text provided does not include the referenced Exhibit 99.1 press release or its financial statements. Accordingly, revenue, net income or loss, cash flow, margins, debt, cash balances, liquidity, and other financial metrics are not clearly provided.
The filing states that consolidated balance sheets, statements of operations, and statements of cash flows contained in Exhibit 99.1 were incorporated by reference into the company’s Form S-8 registration statement.
Changes Versus Prior Comparable Period
The filing text does not provide comparative first-quarter 2022 financial results or quantify changes from the prior comparable period.
Guidance, Outlook, Risks, and Unusual Items
The filing indicates that the referenced press release included a corporate update, but the contents of that update, including guidance, outlook, risks, contingencies, and unusual items, are not included in the provided filing text.
The financial information incorporated by reference is subject to the filing-specific incorporation language. Other information in the report is furnished rather than filed for purposes of Section 18 of the Exchange Act, except where expressly incorporated or otherwise specified.
Investor Verification Items
- Obtain and review Exhibit 99.1 for first-quarter 2022 revenue, operating results, cash flow, cash position, debt, and liquidity.
- Verify any management guidance, clinical or corporate milestones, and risk disclosures in the complete press release.
- Review the incorporated financial statements in the company’s Form S-8 and related filings.
- Confirm whether the company’s liquidity and financing resources support planned operations and development activities.